Kisqali Stock Market Invest

Novartis Kisqali® Demonstrates 28.5% Reduction in Early Breast Cancer Recurrence Risk Sep 16, 2024

Novartis to Unveil Key Data from Breast Cancer and Hematology Studies at SABCS and ASH Meetings Nov 20, 2023